ReviewAnnual review of medicine2012
Vaccines for malaria: how close are we?
Review in Annual review of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Effects of Plasmodium berghei infection on the expression of salivary gland immune-related genes in the Anopheles stephensi mosquito.Malaria journal · 2025Article
- Article
- Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi.Human vaccines & immunotherapeutics · 2020Article
- Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India.Malaria journal · 2019Article
- Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02Malaria journal · 2019Article
- Editorial: Innovative Therapeutic and Immunomodulatory Strategies for Protozoan Infections.Frontiers in cellular and infection microbiology · 2019Article
- Comparative analysis of low complexity regions in Plasmodia.Scientific reports · 2018Article
- Mapping under-5 and neonatal mortality in Africa, 2000-15: a baseline analysis for the Sustainable Development Goals.Lancet (London, England) · 2017Review
- Enhanced acquired antibodies to a chimeric Plasmodium falciparum antigen; UB05-09 is associated with protective immunity against malaria.Parasite immunology · 2017Article
- Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.Vaccine · 2016Article
- Construction of recombinant Mip-FlaA dominant epitope vaccine against Legionella pneumophila and evaluation of the immunogenicity and protective immunity.Immunologic research · 2016Article
- Review
- Detection of G119S ace-1 (R) mutation in field-collected Anopheles gambiae mosquitoes using allele-specific loop-mediated isothermal amplification (AS-LAMP) method.Malaria journal · 2015Article
- Virus-Based Nanoparticles as Versatile Nanomachines.Annual review of virology · 2015Review
- Antimalarial chemotherapy: orally curative artemisinin-derived trioxane dimer esters.Bioorganic & medicinal chemistry letters · 2015Article
- A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.Human vaccines & immunotherapeutics · 2015Article
- Mosquito Akirin as a potential antigen for malaria control.Malaria journal · 2014Article
- A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity.BMC genomics · 2014Article
- Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.Clinical and vaccine immunology : CVI · 2014Article
- Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.Bioorganic & medicinal chemistry letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Vaccines are the most powerful public health tools mankind has created, but malaria parasites are bigger, more complicated, and wilier than the viruses and bacteria that have been conquered or controlled with vaccines. Despite decades of research toward a vaccine for malaria, this goal has remained elusive. Nevertheless, recent advances justify optimism that a licensed malaria vaccine is within reach. A subunit recombinant protein vaccine that affords in the neighborhood of 50% protective efficacy against clinical malaria is in the late stages of clinical evaluation in Africa. Incremental improvements on this successful vaccine are possible and worth pursuing, but the best hope for a highly efficacious malaria vaccine that would improve prospects for malaria eradication may lie with the use of attenuated whole parasites and powerful immune-boosting adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.